Long-term Effectiveness of COVID-19 Vaccines Against Symptomatic and Asymptomatic Infection in the General Population and in Populations at Increased Risk for COVID-19

The Centers for Disease Control and Prevention - ERA is seeking research to evaluate the long-term effectiveness of COVID-19 vaccines against symptomatic and asymptomatic infections. The purpose of this notice of funding opportunity is to support studies that will assess immune response metrics, symptoms, and the development of asymptomatic infection/viral shedding. The studies should be adequately powered to generate product- and variant-specific vaccine effectiveness estimates and to assess risk factors for vaccine breakthrough. Key aspects of this opportunity include: • Long-term follow-up of vaccinated individuals (adults and children) to assess immune response metrics and symptoms • Assessment of risk factors for vaccine breakthrough, including demographic, immunologic, and virologic risk factors • Generation of product- and variant-specific vaccine effectiveness estimates • Evaluation of the development of asymptomatic infection/viral shedding • Support for research to evaluate the long-term effectiveness of COVID-19 vaccines